Clinical trial
Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma
NCT00436618 is registered in ClinicalTrials.gov with Mayo Clinic as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Trial of Everolimus (RAD001) in Relapsed/Refractory Lymphoma
- Lead sponsor
- Mayo Clinic
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- August 31, 2005
- Completion date
- October 9, 2019
- Enrollment
- 277 (actual)
- Sites
- 3
Conditions
As the registry lists them; a condition with its own page is linked.